Recent

% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • pylesm pylesm Aug 21, 2013 1:23 AM Flag

    Mannkind vis a vis Gilead

    Does anyone else see an analogy here? Gilead put a huge amount of effort to get the first once daily HIV pill on the market. Even I was really skeptical, thinking what's the difference; one pill or three, when you can take the three pills just once daily. However, I was wrong. Atripla launched Gilead into the big leagues.

    Seems AfrezzaUser has been steadfast in pointing out the lifestyle advantages; primarily of simply being able to eat a meal without being concerned about timing your mealtime insulin. Having to time every meal, every day, seems to be a HUGE pain.

    If there's any comparison here, it would be Afrezza offers a lot more lifestyle advantages to diabetics than Atripla did to HIV patients. And note the rapid growth in market share for Atripla after it launched, even though it carried a premium price.

    Seems like patients might end up being the driving force along with some really good DTC advertising to get the word out.

 
MNKD
0.7886-0.0469(-5.61%)Aug 26 4:00 PMEDT